Literature DB >> 12565086

Functional relevance of aldosterone for the determination of left ventricular mass.

Christian Delles1, Bernhard M W Schmidt, Hans J Müller, Sebastian Oehmer, Arnfried U Klingbeil, Roland E Schmieder.   

Abstract

In experimental studies, the importance of aldosterone for the development of left ventricular (LV) hypertrophy has been demonstrated. In 120 healthy Caucasian men (aged 25 +/- 3 years; blood pressure, 134 +/- 15/86 +/- 12 mm Hg), we determined LV mass (2-dimensionally guided M-mode echocardiography), urinary aldosterone concentration, and the response of aldosterone to angiotensin II infusion (3.0 ng/kg/min). Seventy-six volunteers took part in a follow-up visit after 2 years when urinary aldosterone concentration and LV mass were determined again. At follow-up, LV mass increased in 42 subjects (by 33 +/- 26 g), whereas in 34 subjects LV mass decreased (by 27 +/- 22 g). Between the 2 groups, only the change in urinary aldosterone concentration over time was significantly different (group with increased LV mass had an increase in urinary aldosterone concentration by 2.5 +/- 5.4 microg/day; group with decreased LV mass had a decrease in urinary aldosterone concentration by 0.7 +/- 4.6; p <0.01 between groups). In accordance, we found significant correlations between changes in LV mass and changes in urinary aldosterone concentration (r = 0.29, p <0.05) and between changes in LV mass and the response of aldosterone to angiotensin II at baseline (r = 0.25, p <0.05). Both changes in aldosterone concentration over time and the response of aldosterone to angiotensin II were related to changes in LV mass over time. These data underscore the importance of aldosterone for the development of LV hypertrophy. This process is already evident in young subjects with apparently small changes in LV mass over a mean follow-up period of 2 years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565086     DOI: 10.1016/s0002-9149(02)03158-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study.

Authors:  Eduardo Pimenta; Richard D Gordon; Ashraf H Ahmed; Diane Cowley; Rodel Leano; Thomas H Marwick; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2011-06-01       Impact factor: 5.958

2.  Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis.

Authors:  Antonello D'Andrea; Pio Caso; Gemma Salerno; Raffaella Scarafile; Giuseppe De Corato; Claudia Mita; Giovanni Di Salvo; Sergio Severino; Sergio Cuomo; Biagio Liccardo; Nicolino Esposito; Raffaele Calabrò
Journal:  Br J Sports Med       Date:  2006-12-18       Impact factor: 13.800

3.  Cardiac effects of anabolic steroids.

Authors:  J R Payne; P J Kotwinski; H E Montgomery
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

4.  The association between left ventricular hypertrophy and biomarkers in patients on continuous ambulatory peritoneal dialysis.

Authors:  Sang-Ho Park; Se-Whan Lee; Seung-Jin Lee; Won-Yong Shin; Dong-Kyu Jin; Hyo-Wook Gil; Jong-Oh Yang; Eun-Young Lee; Sae-Yong Hong
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

5.  Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism.

Authors:  Chi-Sheng Hung; Yi-Lwun Ho; Yi-Yao Chang; Vin-Cent Wu; Xue-Ming Wu; Jen-Kuang Lee; Shih-Chieh Chueh; Yen-Hung Lin; Yuan-Shian Changh; Shao-Yu Yang; Ya-Hui Hu; Ming-Jai Sui; Ming-Fong Chen; Kwan-Dun Wu
Journal:  ScientificWorldJournal       Date:  2013-12-29

Review 6.  Anabolic-androgenic steroids and cardiovascular risk.

Authors:  Jian-Di Liu; Yan-Qing Wu
Journal:  Chin Med J (Engl)       Date:  2019-09-20       Impact factor: 2.628

Review 7.  Left ventricular hypertrophy and renin-angiotensin system blockade.

Authors:  Brett R Cowan; Alistair A Young
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.